National Institute Of Allergy And Infectious Diseases (niaid)
Clinical trials sponsored by National Institute Of Allergy And Infectious Diseases (niaid), explained in plain language.
-
HIV vaccine trial tests new Prime-Boost strategy
⭐️ VACCINE ⭐️ TerminatedThis early-stage study tested whether new HIV vaccines are safe and can trigger an immune response in healthy adults. Researchers gave different combinations of vaccines to 44 participants to see how well they were tolerated. The study was terminated early, so results are limited…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated May 22, 2026 13:54 UTC
-
Ebola vaccine nasal spray tested in humans – study halted early
⭐️ VACCINE ⭐️ TerminatedThis early-stage study tested a new Ebola vaccine given as a nasal spray in 15 healthy adults. The goal was to check safety and whether the vaccine triggers an immune response. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated May 20, 2026 11:56 UTC
-
Lupus drug combo study halted early: what researchers learned
Disease control TerminatedThis study tested two lupus medications—mycophenolate mofetil (MMF) alone or with voclosporin—in 12 adults with moderately severe lupus. The goal was to see if treatment response differs based on a person's immune system type. The trial was terminated early, so results are limite…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 26, 2026 02:24 UTC
-
New drug doses tested to preserve insulin in type 1 diabetes
Disease control TerminatedThis study tested four different doses of a drug called siplizumab in 8 people aged 8 to 45 who were diagnosed with type 1 diabetes within the past 18 months. The goal was to find a safe dose that could help preserve the body's ability to make insulin by changing certain immune c…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 26, 2026 02:22 UTC
-
New drug combo for rare inflammatory disease falls short
Disease control TerminatedThis study tested a drug called elotuzumab combined with prednisone for people with active IgG4-related disease, a rare condition causing swelling and organ damage. The trial was stopped early after enrolling only 8 of the planned 75 participants. The main goal was to check safet…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Mpox drug trial ends early: did tecovirimat help?
Disease control TerminatedThis study tested whether the drug tecovirimat is safe and effective for treating mpox. Researchers compared it to a placebo in 719 people with confirmed or suspected mpox. The main goals were to see if the drug could speed up healing of skin lesions and reduce pain. The trial wa…
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New drug combo aims to tame tough rheumatoid arthritis
Disease control TerminatedThis study tested whether adding a 12-week course of VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis who did not respond well to TNF-inhibitors alone. Only 2 participants were enrolled before the study was stopped. The g…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Shock therapy for arthritis? mild zaps aim to calm Kids' joint pain
Symptom relief TerminatedThis study tested a device that sends mild electrical pulses through the skin to stimulate the vagus nerve, aiming to reduce pain and inflammation in children with juvenile idiopathic arthritis (JIA). The trial enrolled 18 participants aged 5-18 and compared active stimulation to…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated May 26, 2026 02:29 UTC
-
HIV Drug-Hormone interaction study in transgender women ends early
Knowledge-focused TerminatedThis study looked at how feminizing hormone therapy (estrogen) interacts with HIV medications in transgender women living with HIV. Researchers wanted to see if the hormones affect drug levels in the blood. The study enrolled 93 adults and was stopped early, but the goal was to p…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC